Cargando…
Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial
The current curative approaches for ischemia/reperfusion injury on liver transplantation are still under debate for their safety and efficacy in patients with end-stage liver disease. We present the SIMVA statin donor treatment before Liver Transplants study. METHODS. SIMVA statin donor treatment be...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698118/ https://www.ncbi.nlm.nih.gov/pubmed/35862782 http://dx.doi.org/10.1097/TP.0000000000004220 |
_version_ | 1784838736471654400 |
---|---|
author | Pagano, Duilio Bosch, Jaime Tuzzolino, Fabio Oliva, Elisabetta Ekser, Burcin Zito, Giovanni Cintorino, Davide di Francesco, Fabrizio Li Petri, Sergio Ricotta, Calogero Bonsignore, Pasquale Calamia, Sergio Magro, Bianca Trifirò, Gianluca Alduino, Rossella Barbara, Marco Conaldi, Pier Giulio Gallo, Alessia Venuti, Francesca Luca, Angelo Gruttadauria, Salvatore |
author_facet | Pagano, Duilio Bosch, Jaime Tuzzolino, Fabio Oliva, Elisabetta Ekser, Burcin Zito, Giovanni Cintorino, Davide di Francesco, Fabrizio Li Petri, Sergio Ricotta, Calogero Bonsignore, Pasquale Calamia, Sergio Magro, Bianca Trifirò, Gianluca Alduino, Rossella Barbara, Marco Conaldi, Pier Giulio Gallo, Alessia Venuti, Francesca Luca, Angelo Gruttadauria, Salvatore |
author_sort | Pagano, Duilio |
collection | PubMed |
description | The current curative approaches for ischemia/reperfusion injury on liver transplantation are still under debate for their safety and efficacy in patients with end-stage liver disease. We present the SIMVA statin donor treatment before Liver Transplants study. METHODS. SIMVA statin donor treatment before Liver Transplants is a monocentric, double-blind, randomized, prospective tial aiming to compare the safety and efficacy of preoperative brain-dead donors’ treatment with the intragastric administration of 80 mg of simvastatin on liver transplant recipient outcomes in a real-life setting. Primary aim was incidence of patient and graft survival at 90 and 180 d posttransplant; secondary end-points were severe complications. RESULTS. The trial enrolled 58 adult patients (18–65 y old). The minimum follow-up was 6 mo. No patient or graft was lost at 90 or 180 d in the experimental group (n = 28), whereas patient/graft survival were 93.1% (P = 0.016) and 89.66% (P = 0.080) at 90 d and 86.21% (P = 0.041) and 86.2% (P = 0.041) at 180 d in the control group (n = 29). The percentage of patients with severe complications (Clavien-Dindo ≥IIIb) was higher in the control group, 55.2% versus 25.0% in the experimental group (P = 0.0307). The only significant difference in liver tests was a significantly higher gamma-glutamyl transferase and alkaline phosphatase at 15 d (P = 0.017), (P = 0.015) in the simvastatin group. CONCLUSIONS. Donor simvastatin treatment is safe, and may significantly improve early graft and patient survival after liver transplantation, although further research is mandatory. |
format | Online Article Text |
id | pubmed-9698118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-96981182022-11-28 Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial Pagano, Duilio Bosch, Jaime Tuzzolino, Fabio Oliva, Elisabetta Ekser, Burcin Zito, Giovanni Cintorino, Davide di Francesco, Fabrizio Li Petri, Sergio Ricotta, Calogero Bonsignore, Pasquale Calamia, Sergio Magro, Bianca Trifirò, Gianluca Alduino, Rossella Barbara, Marco Conaldi, Pier Giulio Gallo, Alessia Venuti, Francesca Luca, Angelo Gruttadauria, Salvatore Transplantation Original Clinical Science—Liver The current curative approaches for ischemia/reperfusion injury on liver transplantation are still under debate for their safety and efficacy in patients with end-stage liver disease. We present the SIMVA statin donor treatment before Liver Transplants study. METHODS. SIMVA statin donor treatment before Liver Transplants is a monocentric, double-blind, randomized, prospective tial aiming to compare the safety and efficacy of preoperative brain-dead donors’ treatment with the intragastric administration of 80 mg of simvastatin on liver transplant recipient outcomes in a real-life setting. Primary aim was incidence of patient and graft survival at 90 and 180 d posttransplant; secondary end-points were severe complications. RESULTS. The trial enrolled 58 adult patients (18–65 y old). The minimum follow-up was 6 mo. No patient or graft was lost at 90 or 180 d in the experimental group (n = 28), whereas patient/graft survival were 93.1% (P = 0.016) and 89.66% (P = 0.080) at 90 d and 86.21% (P = 0.041) and 86.2% (P = 0.041) at 180 d in the control group (n = 29). The percentage of patients with severe complications (Clavien-Dindo ≥IIIb) was higher in the control group, 55.2% versus 25.0% in the experimental group (P = 0.0307). The only significant difference in liver tests was a significantly higher gamma-glutamyl transferase and alkaline phosphatase at 15 d (P = 0.017), (P = 0.015) in the simvastatin group. CONCLUSIONS. Donor simvastatin treatment is safe, and may significantly improve early graft and patient survival after liver transplantation, although further research is mandatory. Lippincott Williams & Wilkins 2022-07-11 2022-12 /pmc/articles/PMC9698118/ /pubmed/35862782 http://dx.doi.org/10.1097/TP.0000000000004220 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Clinical Science—Liver Pagano, Duilio Bosch, Jaime Tuzzolino, Fabio Oliva, Elisabetta Ekser, Burcin Zito, Giovanni Cintorino, Davide di Francesco, Fabrizio Li Petri, Sergio Ricotta, Calogero Bonsignore, Pasquale Calamia, Sergio Magro, Bianca Trifirò, Gianluca Alduino, Rossella Barbara, Marco Conaldi, Pier Giulio Gallo, Alessia Venuti, Francesca Luca, Angelo Gruttadauria, Salvatore Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial |
title | Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial |
title_full | Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial |
title_fullStr | Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial |
title_full_unstemmed | Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial |
title_short | Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial |
title_sort | donor simvastatin treatment is safe and might improve outcomes after liver transplantation: a randomized clinical trial |
topic | Original Clinical Science—Liver |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698118/ https://www.ncbi.nlm.nih.gov/pubmed/35862782 http://dx.doi.org/10.1097/TP.0000000000004220 |
work_keys_str_mv | AT paganoduilio donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT boschjaime donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT tuzzolinofabio donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT olivaelisabetta donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT ekserburcin donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT zitogiovanni donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT cintorinodavide donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT difrancescofabrizio donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT lipetrisergio donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT ricottacalogero donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT bonsignorepasquale donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT calamiasergio donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT magrobianca donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT trifirogianluca donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT alduinorossella donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT barbaramarco donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT conaldipiergiulio donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT galloalessia donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT venutifrancesca donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT lucaangelo donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial AT gruttadauriasalvatore donorsimvastatintreatmentissafeandmightimproveoutcomesafterlivertransplantationarandomizedclinicaltrial |